Liraglutide in Newly Onset Type 1 Diabetes.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-28

Study Completion Date

2018-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

52 Week Trial of Liraglutide in Type 1 Diabetes

NCT01787916

Type 1 Diabetes

COMPLETED PHASE4

Liraglutide in Type 1 Diabetes

NCT01612468

Diabetes Mellitus, Type 1 Overweight

COMPLETED PHASE4

Liraglutide as add-on to Insulin in Type 1 Diabetes

NCT02092896

Diabetes Diabetes Mellitus, Type 1

COMPLETED PHASE3

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

NCT02443155

Diabetes Diabetes Mellitus, Type 1

COMPLETED PHASE2

Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

NCT01508923

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liraglutide

1.8 mg

Group Type ACTIVE_COMPARATOR

Liraglutide

Intervention Type DRUG

Saline

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liraglutide

Intervention Type DRUG

Placebo

Saline

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Victoza

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 1 diabetes according to WHO criteria diagnosed ≤ 6 weeks before visit 0
* Age 18 - 40 years - both inclusive
* Postprandial C-peptide \> 0.2 nmol/l following sustacal meal test
* Able to understand the written patient information and to give informed consent

Exclusion Criteria

* Type 2 diabetes
* Body mass index \<20 kg/m2
* Pregnancy or unwillingness to use safe contraceptives
* Compromised kidney function (eGFR \< 60 ml/min/1,73m2), dialysis or kidney transplantation at visit 0
* Liver disease with elevated plasma alanine aminotransferase (ALT) \> three times the upper limit of normal at visit 0

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No